Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACT trial of biomarker-guided early clarithromycin in community-acquired pneumonia
2023-507295-40-00Phase 3Authorised
- Sponsor
- Hellenic Institute for the Study of Sepsis
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in community-acquired pneumonia (CAP) comparing Clarithromycin plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Composite treatment success at day 4. Planned start Jan 2024; status: authorised.
02
Drugs
clarithromycin
03
Conditions
community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on 2023-507295-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507295-40-00.